Apollomics Notifies Nasdaq MVLS Deficiency; Regains Vebreltinib Rights
Apollomics Inc. received a notice from Nasdaq on June 18, 2026, indicating non-compliance with the minimum Market Value of Listed Securities (MVLS) requirement of $35 million. The company has 180 days, until December 15, 2026, to regain compliance, with no immediate effect on its listing. Separately, Apollomics terminated its collaboration agreement with Launxp International Co., Ltd. effective June 11, 2026, due to Launxp's failure to pay a $3.8 million upfront balance. This termination resulted in Apollomics regaining global rights to its lead asset, vebreltinib (APL-101), in Asia and other regions outside Mainland China and Macau, and the company has initiated dispute resolution to recover the unpaid amount.
Key Highlights
- Apollomics received a Nasdaq notice on June 18, 2026, for not meeting the $35 million MVLS requirement.
- The company has 180 calendar days, until December 15, 2026, to regain compliance.
- Collaboration and License Agreement with Launxp International Co., Ltd. was terminated effective June 11, 2026.
- Termination was due to Launxp's failure to remit a $3.8 million upfront payment balance plus interest.
- Apollomics initiated dispute resolution on June 18, 2026, to recover the unpaid $3.8 million.
- Apollomics regained previously licensed rights to vebreltinib (APL-101) in Asia.
- Company now holds all global rights to vebreltinib outside Mainland China and Macau.
Price Impact
More from APLM